Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Midazolam Interaction of BI 764198 in Healthy Males
NCT04102462Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of apecotrep in focal segmental glomerulosclerosis (FSGS) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of subjects with drug-related adverse events. Started Oct 2019; status: completed.
02
Drugs
apecotrep
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT04102462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04102462.